• Krystal Biotech average return on tangible equity for 2023 was -13.49, a 41.4% decline from 2022.
• Krystal Biotech average return on tangible equity for 2022 was -23.02, a 60.53% decline from 2021.
• Krystal Biotech average return on tangible equity for 2021 was -14.34, a 40.45% increase from 2020.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.